With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile ...

Novo Nordisk A/S (NYSE:NVO) has made headlines recently by reporting an impressive 18% sales growth in the first half of 2025. This growth highlights the company's significant role in the global ...

While fasting has become a popular trend, particularly for people who hope to lose weight, new UBC Okanagan research suggests ...

Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market.

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

Novo Nordisk A/S (NYSE:NVO) is one of the Reddit Stocks with the Highest Upside Potential. On August 6, the company stated ...

Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...